Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative
neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might …

Polycythemia vera (PV) belongs to the BCR-ABL1–negative myeloproliferative neoplasms
and is characterized by activating mutations in JAK2 and clinically presents with …

Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising
disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential …

In patients with low-risk polycythemia vera, exposure to low-dose Ropeginterferon alfa-2b
(Ropeg) 100 µg every 2 weeks for 2 years was more effective than the standard treatment of …

We investigated the effect of Ropeginterferon alfa‐2b (Ropeg) versus phlebotomy‐only (Phl‐
O) on the neutrophil‐to‐lymphocyte ratio (NLR) in 126 patients randomized in the low …

Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia
vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV …

Anaemia could develop in polycythemia vera (PV) due to phlebotomy-caused iron-
deficiency and cytotoxic effect of cytoreductive therapy. Ropeginterferon alfa-2b treatment …

Aim: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher
risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation …

Interferons are cytokines with immunomodulatory properties and disease-modifying effects
that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years …